GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts
- The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology
- Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality
- The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient care
Approximately
“Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimize clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts,” said Karley Yoder, CEO of Comprehensive Care Ultrasound, GE HealthCare. “Invenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritizing the patient experience with features to improve scan speed and enhance comfort during an exam.”
Invenia ABUS Premium is designed to manage high patient volumes along the breast care pathway, while delivering extraordinary image quality and boosting clinical confidence. The new Verisound™ AI tools can help clinicians work smarter and more efficiently, featuring Scan Quality Assessment for immediate qualitative evaluation during the exam for proper breast coverage and positioning, and Auto Nipple Detection for consistent nipple marker positions. The new Fast Scan tool increases scan speed by up to
For fast, streamlined reading, physicians can use Invenia ABUS Viewer with AI Assistant** to quickly review and interpret patient exams either from their practice or remotely. The integration of AI tools** for enhanced review of ABUS 3D datasets harness intelligent algorithms to assist in detecting and characterizing breast lesions. These tools can help improve clinical confidence and reading efficiency, addressing staff shortages.
The ABUS Premium’s non-invasive design significantly enhances the patient experience, with a patient experience study showing that
"As an early adopter of ABUS, I've experienced the entire evolution of this technology. The Invenia ABUS Premium is superior* with its special AI features, which ensure the breast volume is captured and offer automatic nipple annotation, reducing scanning time and streamlining clinical workflow," said Athina Vourtsis, MD, PhD, Chief Director and Founder of Athena Medical,
Invenia ABUS Premium will be launching in key countries throughout 2025 and received Premarket Approval (PMA) from the
Learn more about GE HealthCare’s Invenia ABUS Premium here: Invenia ABUS Breast Imaging Ultrasound | GE HealthCare (
*Compared to InveniaTM ABUS 2.0.
**AI Assistant available third-party tools include QVCAD™, Koios DS™ Breast, BU-CAD™ and MONCAD ABS. Not available in all regions.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 Arora N, King TA, Jacks LM., Ann Surg Onc, 2010; 17:S211-18. |
2 Pisano et al. NEJM 2005; 353: 1773. |
3 Ref. Ellison-Loschman, et al, PLOS ONE July 2013. |
4 Boyd NF et al. NEJM 2007; 356: 227 |
5 Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087. |
6 FDA PMA P110006 summary of safety and effectiveness |
7 Brem RF, Tabár L, et.al. Radiology. 2015 Mar; 274(3): 663-73. |
8 Stempel et.al., Journal of Breast Imaging 2024, Vol XX, No. XX, 1-10. |
9 Wenhui Ren et. al, Elsevier Acad Radiol 2023; 30:S114–S126. |
10 Shah et.al. Journal of Diagnostic Medical Sonography DOI: 10.1177/8756479313476920 2013. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320743877/en/
GE HealthCare Media Contact
Eric Tatro
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com
Source: GE HealthCare